What question did this study set out to answer?

To explore a biology-driven approach to antiplatelet therapy in relation to thrombotic risk following CABG surgery.

April 24, 2026

Antiplatelet Therapy After CABG—Toward a Mechanistic Approach

Resultado clave

A biology-driven approach to antiplatelet therapy after coronary artery bypass graft surgery is proposed to align treatment with patients' evolving thrombotic risk.

Puntos clave

To explore a biology-driven approach to antiplatelet therapy in relation to thrombotic risk following CABG surgery.
Discussion of biological mechanisms related to thrombotic risk.
Analysis of current antiplatelet therapy strategies post-CABG.
Proposes an innovative, mechanistic framework for antiplatelet therapy.
Highlights the need for personalized treatment based on evolving thrombotic risks.

PICO estructurado

Población

Patients after coronary artery bypass graft (CABG) surgery

Intervención

Antiplatelet therapy aligned with evolving thrombotic risk (biology-driven concept)

Proposes a novel, biology-driven approach to align antiplatelet therapy with evolving thrombotic risk following CABG surgery.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

This Viewpoint discusses a novel, biology-driven concept aligning antiplatelet therapy with evolving thrombotic risk after coronary artery bypass graft (CABG) surgery.

Me gusta

Guardar

Me gusta

Guardar

Cite This Study

Sandner et al. (Wed,) reported a other. A biology-driven approach to antiplatelet therapy after coronary artery bypass graft surgery is proposed to align treatment with patients' evolving thrombotic risk.

synapsesocial.com/papers/69eb0bfa553a5433e34b582e https://doi.org/https://doi.org/10.1001/jamacardio.2026.0840